Cartiaxt (diltiazem) is commonly used to help with managing the symptoms of chronic stable angina, controlling high blood pressure (hypertension), and addressing rapid heart rates in certain atrial arrhythmias. This medication is considered relevant for conditions presenting with systemic imbalance and episodic or fluctuating manifestations of chest discomfort.

This therapeutic approach is primarily applied in addressing symptoms related to physical discomfort, which includes pressure or tightness in the chest. It is applied in scenarios where additional management of discomfort is required and contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability. This therapeutic support highlights the overall benefit: “It supports the heart during difficult episodes by easing distress linked to heightened physiological activity.”

---

Quick Fact: Relief for Episodic Discomfort

It is relevant in contexts involving heightened systemic burden and conditions where symptoms may intensify temporarily. This contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information on Diltiazem

Who can and cannot use Cartiaxt?

Eligibility for Cartiaxt (Diltiazem Hydrochloride) is determined by regulatory bodies based on the patient's existing cardiac condition and life stage. Use is primarily established for adult patients.

Contraindicated Populations (Must Not Use)

Classification	Restricted Condition	Status
Severe Conduction Disease	Sick Sinus Syndrome or Second-/Third-Degree AV Block	Prohibited, unless a functioning pacemaker is present.
Hemodynamic Instability	Severe hypotension (systolic BP < 90 mmHg)	Prohibited.
Arrhythmia Complications	Atrial Fibrillation/Flutter with an accessory bypass tract (e.g., WPW Syndrome)	Prohibited.
Acute Cardiac Events	Acute myocardial infarction with pulmonary congestion	Prohibited.

Age and Condition-Based Restrictions

• Pediatric Patients: Use is not established for children and adolescents; therefore, it is not recommended.
• Older Adults: Use is permitted, but treatment should commence at the lower dose range due to increased likelihood of age-related organ decline.
• Organ Impairment: Conditional use is required for patients with hepatic (liver) or renal (kidney) impairment, with close monitoring advised.
• Pregnancy/Lactation: Use during pregnancy is restricted (advised only if the benefit justifies the risk). Diltiazem is excreted into human milk, requiring a decision to discontinue nursing or the drug.

Interactions with other medicines and products

Cartiaxt (Diltiazem Hydrochloride) has officially documented interaction patterns primarily rooted in its effects on hepatic enzymes and cardiac function. Regulatory labels classify these interactions into pharmacokinetic and pharmacodynamic categories, leading to mandatory restrictions and required caution with numerous co-administered substances.

Documented Pharmacokinetic Interactions

Cartiaxt is documented as a moderate inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and an inhibitor of the P-glycoprotein (P-gp) efflux transporter. This dual inhibition significantly increases the plasma concentrations and systemic exposure of many co-administered medicines, including CYP3A4-metabolized statins (such as Simvastatin) and immunosuppressants (such as Ciclosporin and Tacrolimus). For medicines sensitive to P-gp inhibition, such as Digoxin, this effect increases the risk of higher circulating levels.

Documented Pharmacodynamic Interactions

Co-administration with other medicines that reduce heart rate or depress cardiac conduction, such as Beta-blockers or Digitalis preparations, carries a formally stated risk of additive effects. This may result in pronounced bradycardia (slow heart rate) or disturbances in atrio-ventricular conduction.

Official Restrictions and Substance Interactions

The regulatory profile explicitly lists several agents as contraindicated combinations due to interaction risk, including Pimozide, Lomitapide, and Flibanserin, which are significantly impacted by CYP3A4 inhibition. Consumption of alcohol (ethanol) is documented as having the potential to cause a more rapid release of the extended-release formulation and may also contribute to additive hypotensive effects. Caution regarding potential increased Diltiazem concentrations is noted for patients with pre-existing hepatic impairment.

How Cartiaxt Works

Cartiaxt, containing Diltiazem Hydrochloride, operates through the specific blockade of the Voltage-Gated L-Type Calcium Channel (CaV1.2). This channel is central to the initiation of electrical activity and contraction in both cardiac cells and vascular smooth muscle.

Molecular and Systemic Modulation

The binding of the molecule to the channel pore physically suppresses the influx of extracellular calcium ions (Ca^2+), interrupting the excitation-contraction coupling pathway. In the heart's electrical system, this action causes negative chronotropy (slowing the Sinoatrial node firing rate) and negative dromotropy (depressing Atrioventricular nodal conduction velocity). Concurrently, reduced calcium availability in the myocardium results in negative inotropy (decreased force of contraction).

In arterial smooth muscle, the same molecular inhibition causes cells to relax, resulting in widespread vasodilation and a reduction in Systemic Vascular Resistance (SVR). The combined effects of slowed electrical conduction, reduced contractility, and lowered SVR result in reduced mechanical workload on the heart and decreased myocardial oxygen demand.

How Cartiaxt is Used

Cartiaxt is an extended-release capsule containing Diltiazem Hydrochloride. Its use is standardized by instructions to ensure the correct oral delivery and stable management of cardiovascular conditions.

---

Route and Administration Constraints

• Route of Administration: The medication is approved exclusively for oral use, taken by mouth.
• Swallowing Constraint: The extended-release capsule must be swallowed whole and must not be crushed, chewed, or divided. Altering the capsule will disrupt its sustained-release function.
• Food Intake: It may be administered without regard to food (with or without a meal).

---

Standard Dosing and Frequency

Cartiaxt is intended for a once-daily (q.d.) dosing schedule, taken at approximately the same time each day.

Indication	Initial Dose (Once Daily)	Maximum Recommended Dose (Once Daily)
Hypertension	180 mg to 240 mg	540 mg
Chronic Stable Angina	120 mg to 180 mg	540 mg

Dose Adjustment (Titration): Dose changes, if necessary, are typically conducted at intervals of 7 to 14 days to allow the body to reach a stable therapeutic level before the next adjustment.

---

Population-Specific Use

Labeling includes recommendations for specific patient populations to mitigate physiological variability:

• Older Adults: A lower starting dose of 120 mg once daily is generally advised.
• Hepatic or Renal Impairment: Treatment should begin at the lower end of the dosing range (e.g., 120 mg once daily), with careful monitoring required.

Research Evidence / Overview of Studies for Cartiaxt

Evidence for Use in Managing Chronic Stable Angina

Research exploring Cartiaxt was studied for chronic stable angina and primarily relies on short-term, randomized controlled trials (RCTs) against a placebo or other active treatments in adult patients. Research was designed to measure functional outcomes and symptom measurement. The main outcomes research examined were functional measures like Exercise Tolerance Time and the measurement of symptom frequency (anginal attacks) and relief medicine use during the study period. Findings describe patterns observed in the studies, such as changes measured in the duration of exercise tolerance.

Evidence for Use in High Blood Pressure (Hypertension)

For high blood pressure, the evidence base for the active ingredient in Cartiaxt includes short-term studies and large-scale, long-term comparative trials that span several years. The primary goal research examined was the measurement of changes in both systolic and diastolic blood pressure. These studies report how symptoms evolved in the observed populations, and the data show patterns related to maintaining blood pressure within a measured range over a full 24-hour cycle. Long-term studies monitored outcomes related to systemic or functional imbalance, such as the incidence rates of stroke and heart attack.

Research Gaps and Areas of Uncertainty

The evidence landscape, while robust in key areas, includes several well-documented research limitations. For stable angina, there is limited information for long-term outcomes regarding the medicine’s sustained influence on major, long-term cardiovascular outcomes. For arrhythmias, comparative evidence is lacking from large, long-term RCTs specifically evaluating the extended-release formulation against other standard rate-controlling agents.

In specific populations, such as those with significant impairment of the liver or kidneys, certainty remains low because the results apply only to the populations studied in the primary clinical trials.

Key Studies & References

1. NORDIL Study: Diltiazem vs Diuretics and Beta-Blockers in Hypertension

Common questions about Cartiaxt (FAQ)

---

Q: Can I eat grapefruit or drink grapefruit juice while taking this medication?

Official regulatory documents state that consuming grapefruit or grapefruit juice may need to be limited while taking Cartiaxt. Large amounts of grapefruit products may potentially increase the concentration of the medicine in the body. This increase could raise the risk of experiencing certain side effects, such as muscle problems.

---

Q: What is the correct way to store my tablets?

According to the official product information, Cartiaxt generally does not require any specific temperature restrictions for storage. The medicine is generally recommended to be kept in the original packaging to help maintain stability and quality. This storage method helps protect the tablets from moisture.

---

Q: Is this medication safe to use during pregnancy?

Regulatory information states that Cartiaxt is contraindicated (should not be used) during pregnancy. If pregnancy is suspected or planned, patients are advised by regulatory sources to discontinue use immediately. Discussions about alternative treatments should be had with a healthcare provider.

---

Q: Is it safe to breastfeed while taking this medicine?

Official labeling advises that Cartiaxt is contraindicated (should not be used) while breastfeeding. It is not currently known if the medicine passes into human breast milk, but official information indicates a potential risk that it could affect the nursing infant. Patients should consult a healthcare professional regarding breastfeeding while on this medication.

---

Q: Does this medicine contain sugar, gluten, or common allergens?

Regulatory documents list all inactive ingredients, called excipients. These lists may include substances like lactose, a type of sugar, in some formulations of the tablet. Patients with known allergies or intolerances should carefully review the full excipient list in the official Patient Information Leaflet. Consultation with a healthcare provider may be helpful if there are concerns about these excipients.

---

Q: What happens if I miss a dose of the medicine?

Official patient information provides instructions on handling a missed dose. Regulatory instructions often state that a missed dose should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped. It is typically advised not to take a double dose to make up for a single missed one.

Cartia XT (diltiazem hydrochloride extended-release capsules) must be stored at a Controlled Room Temperature (CRT) of 25 C (77 F). Permitted temperature excursions range from 15 C to 30 C (59 F to 86 F).

---

Protection and Packaging

The product must be kept in conditions that avoid excessive humidity and should be dispensed in a tight, light-resistant container to maintain its stability. A mandatory requirement in the official labeling is to KEEP OUT OF REACH OF CHILDREN.

---

Disposal

Official regulatory labeling does not provide product-specific instructions for discarding unused or expired Cartia XT. Disposal should therefore follow general governmental guidelines for safe handling of unused medicines.